department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

MIFEPRISTONE · pharmadog

pharmadog
drugs
MIFEPRISTONE

drug

patient view →

MIFEPRISTONE

Marketedupdated 2mo ago

by $CORT CORCEPT THERAPEUTICS INC

Approved

community read0 votes

all catalysts(6)

approval · 6

MIFEPRISTONE — FDA approval

MIFEPRISTONE — FDA approval

MIFEPRISTONE — FDA approval

MIFEPRISTONE — FDA approval

MIFEPRISTONE — FDA approval

MIFEPRISTONE — FDA approval

News(0)

no news has mentioned this drug yet

brand

MIFEPRISTONE

generic

MIFEPRISTONE

indication

Cushing's Syndrome

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 27, 2028

~2.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

Aug 22, 2038method-of-use (U-1643)US 10231983
Aug 22, 2038method-of-use (U-1643)US 10314850
Aug 22, 2038method-of-use (U-1643)US 10780097
Jun 19, 2037method-of-use (U-1643)US 10195214
Jun 19, 2037method-of-use (U-1643)US 10842800
Jun 19, 2037method-of-use (U-1643)US 11969435
Jun 19, 2037method-of-use (U-1643)US 12097210
Jan 18, 2037method-of-use (U-1643)US 10151763
Aug 15, 2036method-of-use (U-1643)US 9829495
Aug 12, 2036method-of-use (U-1643)US 10006924
Aug 12, 2036method-of-use (U-1643)US 10495650
Apr 20, 2036method-of-use (U-1643)US 10166242
Apr 20, 2036method-of-use (U-1643)US 10166243
Apr 20, 2036method-of-use (U-1643)US 10660904
Apr 20, 2036method-of-use (U-1643)US 9943526
Mar 5, 2033method-of-use (U-1643)US 10500216
Nov 15, 2032method-of-use (U-1643)US 10842801
Aug 27, 2028method-of-use (U-1643)US 89213482.1y

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 3

tagApproval44 co-mentions · 22 sources
tagSmall Molecule22 co-mentions · 22 sources
companyEvita Solutions LLC1 co-mentions · 1 sources

Trials studying MIFEPRISTONE

phase2A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancerrecruitingn=201
—Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortionterminatedn=129
phase4Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)completedn=1,113
phase2RESET-medication Glucocorticoid Receptor (GR) Blockade As Disease Modifying Treatment for Depression with Childhood Traumacompletedn=158
phase2REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonismrecruitingn=60
phase2Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiencyterminatedn=3